Acetaminophen Formulation with N-acetylcysteine for Liver Toxicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Acetaminophen overdose leads to liver toxicity due to depletion of glutathione, necessitating rapid counteraction with sulfhydryl compounds like N-acetylcysteine, but existing formulations face challenges such as unpleasant taste and chemical incompatibility, and the need for early administration within 8 hours post-overdose.

Innovation Solution

A solid oral dosage form combining acetaminophen with a glutathione replenishing agent, such as N-acetylcysteine, in a physically separated and masked form, utilizing various tablet designs like tablet-in-tablet, core-in-cup, and multi-particulate structures to ensure rapid detoxification and improved palatability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If acetaminophen is administered to treat pain and fever, then therapeutic effect is achieved, but liver toxicity occurs due to glutathione depletion

Engineering Contradiction:

Improvetherapeutic safetyVSAvoidliver toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by including a sulfhydryl compound (antidote) in the dosage form that proactively counteracts the toxic effects of acetaminophen before they can cause liver damage. The sulfhydryl compound is formulated to be released and act against NAPQI toxicity, preventing hepatocellular necrosis rather than treating it after occurrence.

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The patent merges the therapeutic agent (acetaminophen) with the protective agent (sulfhydryl compound) into a single combined dosage form. This integration ensures that both the pain-relieving/fever-reducing effects and the liver protection effects are delivered simultaneously in a unified pharmaceutical product.

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If sulfhydryl compounds are administered as antidote, then liver protection is achieved, but unpleasant taste and chemical incompatibility issues arise

Engineering Contradiction:

Improveliver protectionVSAvoidunpleasant taste

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies segmentation by using a multi-layer tablet structure where the sulfhydryl compound is isolated in a separate layer from the acetaminophen layer. This physical separation prevents direct chemical interaction between the two compounds while ensuring both are delivered to the gastrointestinal tract, thereby maintaining liver protection efficacy while avoiding taste issues.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses an intermediary barrier layer between the sulfhydryl compound and acetaminophen layers. This intermediate layer prevents direct chemical contact that would cause incompatibility, while still allowing the sulfhydryl compound to fulfill its protective function when needed.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If sulfhydryl compounds are administered early within 8 hours, then optimal protection is achieved, but delayed administration reduces effectiveness

Engineering Contradiction:

Improveprotection efficacyVSAvoidadministration delay

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by formulating the sulfhydryl compound to be immediately available upon ingestion of the combined dosage form. The compound is positioned to act preemptively against potential toxicity even if the full therapeutic effect of acetaminophen has not yet occurred, ensuring protection begins as soon as the dosage form is administered rather than waiting for toxicity to manifest.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination product effectively counteracts acetaminophen-induced liver toxicity by replenishing glutathione, reducing hepatotoxicity and improving safety by providing a fixed dose combination that can be administered promptly, even beyond the optimal 8-hour window, while minimizing side effects and chemical interactions.

Implementation Method 1

NAPQI is detoxified by conjugation with glutathione, a sulfhydryl donor, so that it can be excreted into bile or further metabolized into less harmful products.

Methodology Applied

Scientific EffectDetoxification by conjugation: Chemical Bonding

Implementation Method 2

The barrier layer is non-permeable to both acetaminophen and the glutathione replenishing agent. This barrier function may be achieved by appropriate implementation of design factors such as layer thickness, density, material composition, etc.

Methodology Applied

Scientific EffectPhysical separation: Physical Containment

Data Source

PatentUS11590090B2Acetaminophen formulation with protection against toxic effects of overdose

Publication Date: 2023.02.28 ANZEN PHARM LLC

AI summary

An oral pharmaceutical dosage form that comprises both acetaminophen and a glutathione replenishing agent, such as N-acetylcysteine. This allows co-administering the glutathione replenishing agent along with acetaminophen, which may be beneficial in rapidly counteracting the toxic effects of acetaminophen overdose. The oral dosage form could be in the form of a tablet or capsule. The dosage form may be designed to compartmentally separate the glutathione replenishing agent from having chemical interaction with the acetaminophen. The dosage form may be designed to mask the taste or smell of the glutathione replenishing agent.